miR-7, miR-10a and miR-143 Expression May Predict Response to Bevacizumab Plus Chemotherapy in Patients with Metastatic Colorectal Cancer

References

• Ha M, Kim VN. Regulation of microRNA biogenesis. Nat Rev Mol Cell Biol. 2014;15:509–524.
   PubMed Web of Science ®Google Scholar
• Lujambio A, Lowe SW. The microcosmos of cancer. Nature. 2012;482:347–355. doi:10.1038/nature10888
   PubMed Web of Science ®Google Scholar
• Peng W, Liu YN, Zhu SQ, et al. The correlation of circulating pro-angiogenic miRNAs’ expressions with disease risk, clinicopathological features, and survival profiles in gastric cancer. Cancer Med. 2018;7:3773–3791. doi:10.1002/cam4.1618
   Web of Science ®Google Scholar
• Azam F, Mehta S, Harris AL. Mechanisms of resistance to antiangiogenesis therapy. Eur J Cancer. 2010;46:1323–1332. doi:10.1016/j.ejca.2010.02.020
   PubMed Web of Science ®Google Scholar
• Hon KW, Abidin SAZ, Othman I, et al. Insights into the role of microRNAs in colorectal cancer (CRC) metabolism. Cancers. 2020;12:1–17.
   Web of Science ®Google Scholar
• Giles KM, Brown RAM, Epis MR, et al. miRNA-7-5p inhibits melanoma cell migration and invasion. Biochem Biophys Res Commun. 2013;430:706–710. doi:10.1016/j.bbrc.2012.11.086
   PubMed Web of Science ®Google Scholar
• Shi Y, Luo X, Li P, et al. miR-7-5p suppresses cell proliferation and induces apoptosis of breast cancer cells mainly by targeting REGγ. Cancer Lett. 2015;358:27–36. doi:10.1016/j.canlet.2014.12.014
   Web of Science ®Google Scholar
• Nagano Y, Toiyama Y, Okugawa Y, et al. MicroRNA-7 is associated with malignant potential and poor prognosis in human colorectal cancer. Anticancer Res. 2016;36:6521–6526. doi:10.21873/anticanres.11253
   Web of Science ®Google Scholar
• Suto T, Yokobori T, Yajima R, et al. MicroRNA-7 expression in colorectal cancer is associated with poor prognosis and regulates cetuximab sensitivity via EGFR regulation. Carcinogenesis. 2015;36:338–345. doi:10.1093/carcin/bgu242
   PubMed Web of Science ®Google Scholar
• Chang C-H, Fan T-C, Yu J-C, et al. The prognostic significance of RUNX2 and miR-10a/10b and their inter-relationship in breast cancer. J Transl Med. 2014;12:257. doi:10.1186/s12967-014-0257-3
   Web of Science ®Google Scholar
• Long M-J, Wu F-X, Li P, et al. MicroRNA-10a targets CHL1 and promotes cell growth, migration and invasion in human cervical cancer cells. Cancer Lett. 2012;324(2):186–196. doi:10.1016/j.canlet.2012.05.022
   PubMed Web of Science ®Google Scholar
• Jia H, Zhang Z, Zou D, et al. MicroRNA-10a is down-regulated by DNA methylation and functions as a tumor suppressor in gastric cancer cells. PLoS One. 2014;9:e88057. doi:10.1371/journal.pone.0088057
   PubMed Web of Science ®Google Scholar
• Xiong G, Huang H, Feng M, et al. MiR-10a-5p targets TFAP2C to promote gemcitabine resistance in pancreatic ductal adenocarcinoma. J Exp Clin Cancer Res. 2018;37:1–15. doi:10.1186/s13046-018-0739-x
   Web of Science ®Google Scholar
• Moreno EC, Pascual A, Prieto-Cuadra D, et al. Novel molecular characterization of colorectal primary tumors based on miRNAs. Cancers. 2019:11. doi:10.3390/cancers11030346
   Web of Science ®Google Scholar
• Garcia J, Hurwitz HI, Sandler AB, et al. Bevacizumab (Avastin®) in cancer treatment: a review of 15 years of clinical experience and future outlook. Cancer Treat Rev. 2020;86:102017. doi:10.1016/j.ctrv.2020.102017
   PubMed Web of Science ®Google Scholar
• Bennouna J, Sastre J, Arnold D, et al. Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised Phase 3 trial. Lancet Oncol. 2013;14:29–37. doi:10.1016/S1470-2045(12)70477-1
   PubMed Web of Science ®Google Scholar
• Giles KM, Brown RAM, Ganda C, et al. microRNA-7-5p inhibits melanoma cell proliferation and metastasis by suppressing RelA/NF-κB. Oncotarget. 2016;7:31663–31680. doi:10.18632/oncotarget.9421
   PubMedGoogle Scholar
• Ge X, Zheng L, Huang M, et al. MicroRNA expression profiles associated with acquired gefitinib-resistance in human lung adenocarcinoma cells. Mol Med Rep. 2015;11:333–340. doi:10.3892/mmr.2014.2757
   Web of Science ®Google Scholar
• Yang I-P, Tsai H-L, Miao Z-F, et al. Development of a deregulating microRNA panel for the detection of early relapse in postoperative colorectal cancer patients. J Transl Med. 2016;14:108. doi:10.1186/s12967-016-0856-2
   Web of Science ®Google Scholar
• Meng X, Joosse SA, Müller V, et al. Diagnostic and prognostic potential of serum miR-7, miR-16, miR-25, miR-93, miR-182, miR-376a and miR-429 in ovarian cancer patients. Br J Cancer. 2015;113:1358–1366. doi:10.1038/bjc.2015.340
   PubMed Web of Science ®Google Scholar
• Fan X, Liu M, Tang H, et al. MicroRNA-7 exerts antiangiogenic effect on colorectal cancer via ERK Signaling. J Surg Res. 2019;240:48–59. doi:10.1016/j.jss.2019.02.035
   Web of Science ®Google Scholar
• Chen W-Q. Role of microRNA-7 in digestive system malignancy. World J Gastrointest Oncol. 2016;8:121. doi:10.4251/wjgo.v8.i1.121
   Web of Science ®Google Scholar
• Hassel D, Cheng P, White MP, et al. MicroRNA-10 regulates the angiogenic behavior of zebrafish and human endothelial cells by promoting vascular endothelial growth factor signaling. Circ Res. 2012;111:1421–1433. doi:10.1161/CIRCRESAHA.112.279711
   Web of Science ®Google Scholar
• Wang X, Ling CC, Li L, et al. MicroRNA-10a/10b represses a novel target gene Mib1 to regulate angiogenesis. Cardiovasc Res. 2016;110:140–150. doi:10.1093/cvr/cvw023
   Web of Science ®Google Scholar
• Sun W, Ma Y, Chen P, et al. MicroRNA-10a silencing reverses cisplatin resistance in the A549/cisplatin human lung cancer cell line via the transforming growth factor-β/Smad2/STAT3/STAT5 pathway. Mol Med Rep. 2015;11(5):3854–3859. doi:10.3892/mmr.2015.3181
   Web of Science ®Google Scholar
• Pratama MY, Pascut D, Massi MN, et al. The role of microRNA in the resistance to treatment of hepatocellular carcinoma. Ann Transl Med. 2019;7(20):577. doi:10.21037/atm.2019.09.142
   Web of Science ®Google Scholar
• Kiss I, Mlčochová J, Součková K, et al. MicroRNAs as outcome predictors in patients with metastatic colorectal cancer treated with bevacizumab in combination with FOLFOX. Oncol Lett. 2017;14:743–750. doi:10.3892/ol.2017.6255
   PubMed Web of Science ®Google Scholar
• Son JC, Jeong HO, Park D, et al. MiR-10a and miR-204 as a potential prognostic indicator in low-grade gliomas. Cancer Inform. 2017:16. doi:10.1177/1176935117702878
   Web of Science ®Google Scholar
• Weiss FU, Marques IJ, Woltering JM, et al. Retinoic acid receptor antagonists inhibit miR-10a expression and block metastatic behavior of pancreatic cancer. Gastroenterology. 2009;137:2136–2137. doi:10.1053/j.gastro.2009.08.065
   PubMed Web of Science ®Google Scholar
• Yu T, Liu L, Li J, et al. MiRNA-10a is upregulated in NSCLC and may promote cancer by targeting PTEN. Oncotarget. 2015;6:30239–30250. doi:10.18632/oncotarget.4972
   PubMed Web of Science ®Google Scholar
• Zhi Y, Xie X, Wang R, et al. Serum level of miR-10-5p as a prognostic biomarker for acute myeloid leukemia. Int J Hematol. 2015;102:296–303. doi:10.1007/s12185-015-1829-6
   PubMed Web of Science ®Google Scholar
• Qian X, Yu J, Yin Y, et al. MicroRNA-143 inhibits tumor growth and angiogenesis and sensitizes chemosensitivity to oxaliplatin in colorectal cancers. Cell Cycle. 2013;12:1385–1394. doi:10.4161/cc.24477
   PubMed Web of Science ®Google Scholar
• Bai JW, Xue HZ, Zhang C. Down-regulation of microRNA-143 is associated with colorectal cancer progression. Eur Rev Med Pharmacol Sci. 2016;20:4682–4687.
   Web of Science ®Google Scholar